CREEK & RIVER (4763) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
20 Jul, 2026Executive summary
Achieved record-high sales and profits for Q3, including and excluding the newly consolidated Takahashi Shoten Group, with net sales for the nine months ended November 30, 2025, rising 19.5% YoY to ¥45,551 million and operating profit up 26.2%.
Quarterly net profit exceeded plan, with strong progress in line with forecasts, and comprehensive income increased 58.4% YoY to ¥3,160 million.
Six out of eight business categories posted increased revenue and profits compared to the previous quarter.
Financial highlights
Q3 sales: ¥45,551 million (up 20% YoY); operating profit: ¥3,768 million (up 26% YoY); net profit: ¥3,098 million (up 53% YoY); ordinary profit: ¥3,723 million.
Gross profit margin: 36.5% (down 0.9pt YoY); operating profit margin: 8.3% (up 0.5pt YoY); gross profit rose to ¥16,624 million.
Takahashi Shoten Group contributed ¥4.9 billion in sales and ¥500 million in operating profit for the full year.
Equity ratio decreased to 41.0% from 58.6% at prior year-end due to increased borrowings and asset expansion; net assets rose to ¥18,369 million.
Basic earnings per share for the period was ¥146.46, up from ¥94.87 YoY.
Outlook and guidance
Full-year sales forecast: ¥60,000 million (up 19% YoY); operating profit: ¥5,000 million (up 38% YoY); net profit: ¥3,200 million (up 42% YoY); ordinary profit: ¥5,000 million.
Basic earnings per share forecasted at ¥149.88 for the full year.
Plans to increase sales in all categories, targeting double-digit profit growth.
Dividend per share planned at ¥45, with a payout ratio policy of 30%.
Latest events from CREEK & RIVER
- Sales up 1% but operating profit down 20.2% YoY; strong full-year recovery forecast.4763
Q1 202420 Jul 2026 - Sales up 2.3% but operating profit down 15.6%; AI/DX and overseas growth prioritized.4763
Q2 202420 Jul 2026 - Sales up 1% YoY, profits down double digits, dividend cut, treasury buyback and new initiatives.4763
Q3 202520 Jul 2026 - Record sales and lower profits in FY2025; strong growth and higher dividends forecast for FY2026.4763
Q4 202520 Jul 2026 - Record sales and profit growth, with acquisitions fueling further expansion.4763
Q1 202620 Jul 2026 - Net sales rose 8.7% and profit attributable to owners of parent surged 50.7%.4763
Q2 202620 Jul 2026 - Record sales and double-digit profit growth, with sales growth forecast to continue.4763
Q4 202620 Jul 2026 - Record Q1 sales and profits, driven by creative, medical, and incubation growth.4763
Q1 202720 Jul 2026